Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

1(50.0%)

Phase 3

1(50.0%)

2Total

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04873427Terminated

In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies

Role: lead

NCT04400799Phase 3Terminated

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Role: collaborator

NCT03934515Completed

End-Tidal CO2 (etCO2) and pH in the Correct Naso-gastric Tube Placement

Role: lead

NCT03662360Not ApplicableCompleted

Elderly Demented Patients: Aromatherapy Complementary to Psychopharmacotherapy Psychological Disorders and BPSD Behavior

Role: lead

NCT04002570Completed

Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients

Role: lead

All 5 trials loaded